Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C40H57N5O2 |
Molecular Weight | 639.9129 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=NC=C1CN2CCC(CC2)N(CCCCCCCN3CC[C@H](C3)C(C(N)=O)(C4=CC=CC=C4)C5=CC=CC=C5)C(C)C
InChI
InChIKey=FJADIVYKWUDMEW-PSXMRANNSA-N
InChI=1S/C40H57N5O2/c1-32(2)45(37-21-27-44(28-22-37)30-33-29-42-23-19-38(33)47-3)25-14-6-4-5-13-24-43-26-20-36(31-43)40(39(41)46,34-15-9-7-10-16-34)35-17-11-8-12-18-35/h7-12,15-19,23,29,32,36-37H,4-6,13-14,20-22,24-28,30-31H2,1-3H3,(H2,41,46)/t36-/m1/s1
Molecular Formula | C40H57N5O2 |
Molecular Weight | 639.9129 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:32:51 GMT 2023
by
admin
on
Sat Dec 16 11:32:51 GMT 2023
|
Record UNII |
EPR5GNZ7KS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
EPR5GNZ7KS
Created by
admin on Sat Dec 16 11:32:51 GMT 2023 , Edited by admin on Sat Dec 16 11:32:51 GMT 2023
|
PRIMARY | |||
|
690999-15-6
Created by
admin on Sat Dec 16 11:32:51 GMT 2023 , Edited by admin on Sat Dec 16 11:32:51 GMT 2023
|
PRIMARY | |||
|
10371936
Created by
admin on Sat Dec 16 11:32:51 GMT 2023 , Edited by admin on Sat Dec 16 11:32:51 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
The present studies characterize the in vitro and in vivo pharmacological properties of this molecule in comparison to other marketed antimuscarinics agents. In radioligand binding studies, TD-6301 was found to possess high affinity for human M(2) muscarinic receptor (K(i)=0.36 nM) and was 31, 36, 2 and 128-fold selective for the human M(2) muscarinic receptor compared to the M(1), M(3), M(4) and M(5) muscarinic receptors, respectively. TD-6301 was more potent in inhibiting volume-induced bladder contractions (ID(50)=0.075 mg/kg) compared to oxotremorine-induced salivation (ID(50)=1.0 mg/kg) resulting in a bladder/salivary gland selectivity ratio greater than that observed for tolterodine, oxybutynin, darifenacin and solifenacin.
|